BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33040275)

  • 21. Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment.
    Perfetti V; Casarini S; Palladini G; Vignarelli MC; Klersy C; Diegoli M; Ascari E; Merlini G
    Blood; 2002 Aug; 100(3):948-53. PubMed ID: 12130507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis.
    Nevone A; Girelli M; Mangiacavalli S; Paiva B; Milani P; Cascino P; Piscitelli M; Speranzini V; Cartia CS; Benvenuti P; Goicoechea I; Fazio F; Basset M; Foli A; Nanci M; Mazzini G; Caminito S; Sesta MA; Casarini S; Rognoni P; Lavatelli F; Petrucci MT; Olimpieri PP; Ricagno S; Arcaini L; Merlini G; Palladini G; Nuvolone M
    Leukemia; 2022 Aug; 36(8):2076-2085. PubMed ID: 35610346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diverse patterns of antibody variable gene repertoire disruption in patients with amyloid light chain (AL) amyloidosis.
    Chen EC; Rubinstein S; Soto C; Bombardi RG; Day SB; Myers L; Zaytsev A; Majedi M; Cornell RF; Crowe JE
    PLoS One; 2020; 15(7):e0235713. PubMed ID: 32634163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside.
    Basset M; Nuvolone M; Palladini G; Merlini G
    Expert Rev Hematol; 2020 Sep; 13(9):1003-1015. PubMed ID: 32721177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunoglobulin light chain, Blimp-1 and cytochrome P4501B1 peptides as potential vaccines for AL amyloidosis.
    Flies A; Ahmadi T; Parks AJ; Prokaeva T; Weng L; Rolfe SS; Seldin DC; Sherr DH
    Immunol Cell Biol; 2012 May; 90(5):528-39. PubMed ID: 21894172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Detection of abnormal plasma cells in bone marrow contributes to the diagnosis of primary systemic light chain amyloidosis-review].
    Hu Y; Zhu P
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1251-5. PubMed ID: 23114159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A reappraisal of immunoglobulin variable gene primers and its impact on assessing clonal relationships between PB B cells and BM plasma cells in AL amyloidosis.
    Katoh N; Poshusta TL; Manske MK; Dispenzieri A; Gertz MA; Abraham RS; Ramirez-Alvarado M
    J Clin Immunol; 2011 Dec; 31(6):1029-37. PubMed ID: 21909811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T cell landscape and dynamics in immunoglobulin light chain amyloidosis before and after daratumumab-based therapy.
    Wang Y; Xu L; Zhao W; Chen X; Wen L; Duan W; Yu XJ; De Zhou F; Liu Y; Hao J; Huang X; Lu J; Ge Q
    Clin Transl Med; 2021 Nov; 11(11):e582. PubMed ID: 34845849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis.
    Parrondo RD; Majeed U; Sher T
    Br J Haematol; 2020 Dec; 191(5):673-681. PubMed ID: 32298469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis.
    Muchtar E; Dispenzieri A; Jevremovic D; Dingli D; Buadi FK; Lacy MQ; Gonsalves W; Warsame R; Kourelis TV; Hayman SR; Kapoor P; Leung N; Russell S; Lust JA; Lin Y; Go RS; Zeldenrust S; Kyle RA; Rajkumar SV; Kumar SK; Gertz MA
    Amyloid; 2020 Mar; 27(1):13-16. PubMed ID: 31544536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis.
    Hammons L; Brazauskas R; Pasquini M; Hamadani M; Hari P; D'Souza A
    Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):105-111. PubMed ID: 28830801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis.
    Klimtchuk ES; Prokaeva TB; Spencer BH; Gursky O; Connors LH
    Amyloid; 2017 Jun; 24(2):115-122. PubMed ID: 28632419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden.
    Comenzo RL; Zhang Y; Martinez C; Osman K; Herrera GA
    Blood; 2001 Aug; 98(3):714-20. PubMed ID: 11468171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis.
    Puig N; Paiva B; Lasa M; Burgos L; Perez JJ; Merino J; Moreno C; Vidriales MB; Toboso DG; Cedena MT; Ocio EM; Lecumberri R; García de Coca A; Labrador J; Gonzalez ME; Palomera L; Gironella M; Cabañas V; Casanova M; Oriol A; Krsnik I; Pérez-Montaña A; de la Rubia J; de la Puerta JE; de Arriba F; Prosper F; Martinez-Lopez J; Lecrevisse Q; Verde J; Mateos MV; Lahuerta JJ; Orfao A; San Miguel JF
    Leukemia; 2019 May; 33(5):1256-1267. PubMed ID: 30542145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dysregulation of miRNAs in AL amyloidosis.
    Weng L; Spencer BH; SoohHoo PT; Connors LH; O'Hara CJ; Seldin DC
    Amyloid; 2011 Sep; 18(3):128-35. PubMed ID: 21834602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome.
    Tovar N; Rodríguez-Lobato LG; Cibeira MT; Magnano L; Isola I; Rosiñol L; Bladé J; Fernández de Larrea C
    Amyloid; 2018 Jun; 25(2):79-85. PubMed ID: 29482381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent advances in understanding and treating immunoglobulin light chain amyloidosis.
    Badar T; D'Souza A; Hari P
    F1000Res; 2018; 7():. PubMed ID: 30228867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis.
    Abraham RS; Ballman KV; Dispenzieri A; Grill DE; Manske MK; Price-Troska TL; Paz NG; Gertz MA; Fonseca R
    Blood; 2005 Jan; 105(2):794-803. PubMed ID: 15388584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical presentation and prognosis of immunoglobulin light-chain amyloidosis with high percentage of bone marrow plasma cells.
    Zhang CL; Qiu Y; Shen KN; Miao HL; Feng J; Cao XX; Zhang L; Jiang XY; Zhou DB; Li J
    Leuk Res; 2019 Jun; 81():19-24. PubMed ID: 30981853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Classic features of primary systemic amyloidosis (AL amyloidosis) leading to diagnosis of plasma cell myeloma.
    Tan KW; Zhu B; Behrens E; Tarbox MB
    Dermatol Online J; 2019 Sep; 25(9):. PubMed ID: 31738847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.